Sitemap > News > Psychiatric, Addictive & Sleep Disorders
- ABILIFY (aripiprazole) Supplemental New Drug Application For Pediatric Patients With Schizophrenia Accepted For Priority Review By The U.S. Food And Drug Administration
- Labopharm Initiates Phase III Clinical Study for Once-Daily Formulation of Trazodone
- NovaDel Announces Positive Data from Two Studies Comparing Zolpidem Oral Spray to Ambien(R) Tablets
- EPIX Pharmaceuticals Presents Findings from PRX-00023 Phase 3 Clinical Trial
- DEPOMED INITIATES DOSING OF PATIENTS IN PHASE 2 TRIAL FOR GABAPENTIN GR FOR THE TREATMENT OF MENOPAUSAL HOT FLASHES
- Cephalon Receives FDA Approval of NUVIGIL(TM) for the Treatment of Excessive Sleepiness Associated with Three Disorders
- Memory Pharmaceuticals Establishes Plans for Clinical Program for MEM 3454 in Schizophrenia
- Shire Receives Approvable Letter from FDA for INTUNIV™ (guanfacine) Extended Release, a Nonstimulant for the Treatment of ADHD
- FDA Issues Approvable Letter for RISPERDAL
- Neurogen Announces Positive Results for Proprietary Insomnia Drug in Two Chronic Insomnia Clinical Trials
- ACADIA Pharmaceuticals Initiates Phase IIb Clinical Trial with ACP-104 in Patients with Schizophrenia
- Catalyst Pharmaceutical Partners, Inc. Initiates U.S. Phase II Clinical Trial of CPP-109 in Patients With Cocaine Dependence
- ABILIFY® (aripiprazole) Supplemental New Drug Application Receives Priority Review by U.S. Food And Drug Administration for Adjunctive Treatment in Adults With Major Depressive Disorder
- CHMP approves labelling update of Acomplia® in Europe and confirms the positive benefit-risk profile of the product except in patients suffering from ongoing major depression
- Biovail Provides Update on BVF-033
- Targacept Presents Data from TRIDMAC Trial Showing Positive Effects of Mecamylamine as Augmentation Treatment for Depressed Patients
- BioLineRx Initiates Phase II Trial of BL-1020, a First in Class GABA-Enhanced Antipsychotic for the Treatment of Schizophrenia
- Sepracor Submits LUNIVIA(R) (LUNESTA(R) in U.S.) Marketing Authorization Application (MAA) for Europe
- Valeant Pharmaceuticals Announces Full Enrollment of First Retigabine Phase 3 Epilepsy Study
- Jazz Pharmaceuticals, Inc. Announces Submission of Complete Responses to FDA Approvable Letters for Luvox CR and Luvox
- Allon and TURNS expand collaboration for Phase II schizophrenia trial
- Wyeth Pharmaceuticals and Solvay Pharmaceuticals, Inc. Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
- DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
- Neurocrine Announces PDUFA Action Date of December 12, 2007 for Indiplon Capsules
- New Data Suggest Cymbalta® Reduced Pain in Fibromyalgia Patients With and Without Depression
- FDA Approves RISPERDAL® to Treat Adolescents With Schizophrenia and Children and Adolescents With Bipolar Mania
- Targacept Announces Initiation of Phase IIb Development of AZD3480 (TC-1734) for Cognitive Deficits in Schizophrenia
- Memory Pharmaceuticals Commences Phase 1 Clinical Program for R4996/MEM 63908
- Shire Undertakes Voluntary Market Withdrawal of a Limited Portion of Daytrana Product
- OVATION FURTHER ADVANCES DEVELOPMENT PIPELINE WITH NEW PHASE III EPILEPSY STUDY
- Clinical Data Announces Positive Results from Phase III Pivotal Trial of Vilazodone for Depression
- Evotec Reports Details of the Positive Proof-of-Concept Phase II Study in Insomnia with EVT 201
- Nabi Biopharmaceuticals Announces Continued Positive NicVAX Phase 2b Data at Nine Months
- Evotec Reports Details of the Positive Proof-of-Concept Phase II Study in Insomnia with EVT 201
- TorreyPines Therapeutics Completes Phase I Multiple Dose Clinical Trial of NGX267, A Selective M1 Agonist for the Potential Treatment of Cognitive Impairment Associated with Schizophrenia
- Allon commences Phase II schizophrenia trial and updates clinical progress
- Alexza to Initiate the First Phase 3 Trial for AZ-004 (Staccato(R) Loxapine) in Late Q1 2008
- Depomed Completes Patient Enrollment in Phase 2 Trial for Gabapentin GR for the Treatment of Menopausal Hot Flashes
- Arena Pharmaceuticals Announces Positive Phase 2 Clinical Trial Results of APD125 for the Treatment of Insomnia
- Labopharm completes enrolment for Phase III clinical study for its once-daily trazodone antidepressant drug
- Vanda Pharmaceuticals Submits Iloperidone New Drug Application
- Lu AA21004 shows highly significant results in clinical phase II trial
- Lilly Announces Updates to the Zyprexa and Symbyax U.S. Labels
- Topline Findings from Comparative Analysis of INVEGA™ and Quetiapine in Schizophrenia to be Postered at the 20th Annual U.S. Psychiatric and Mental Health Congress
- NOVEN ANNOUNCES RESULTS OF PHASE 3 CLINICAL STUDY OF ONCE-DAILY LITHIUM PRODUCT
- INVEGA™ significantly reduced symptoms of schizophrenia compared to SEROQUEL® in acutely ill, hospitalized patients
- Evotec Reports Positive Top-Line Results in Phase II Study with EVT 201 in Elderly Insomniacs with Daytime Sleepiness
- Forest Laboratories, Inc. and Gedeon Richter Announce Results of Phase II-B Study for RGH-188 as a Treatment for Schizophrenia
- FDA ISSUES APPROVABLE LETTER FOR STAVZOR™ DELAYED RELEASE VALPROIC ACID CAPSULES
- Results of VYVANSE™ (lisdexamfetamine dimesylate) Pivotal Trial in Adult ADHD Presented at Major Scientific Meeting
- Aradigm Corporation Reports Initial Human Data on a Novel Approach to Treatment of Tobacco Smoking Addiction Using its AERx Essence(R) Nicotine Inhaler
- BioLineRx Announces Positive Results from Phase 2a Interim Trial Analysis of BL-1020 for the Treatment of Patients with Schizophrenia
- EPIX Pharmaceuticals Reports Preliminary Findings from Phase 1b Clinical Trial of Novel 5-HT6 Drug Candidate
- Vanda Pharmaceuticals\' VSF-173 Excessive Sleepiness Phase II Clinical Trial Suggests Wake-Promoting Properties
- Sciele Pharma and Addrenex Announce Initiation of Pivotal Phase III Trials for Clonicel for ADHD
- Fabre Kramer Pharmaceuticals receives decision from FDA on gepirone ER for major depressive disorder
- Feature Bullet Nabi Biopharmaceuticals Announces Successful Completion of NicVAX® Phase 2b Trial
- Acrux developing nicotine spray to help smokers quit
- Repligen Reports Positive Phase 2a Clinical Trial Results of RG2417 for Symptoms of Bipolar Disorder
- Seroquel XR Receives Approval from FDA for Maintenance Treatment of Schizophrenia
- ABILIFY® (aripiprazole) Supplemental New Drug Application For The Treatment Of Pediatric Patients With Bipolar I Disorder Accepted For Priority Review By The U.S. Food And Drug Administration
- U.S. Food and Drug Administration Approves ABILIFY (aripiprazole) as the First Medication for Add-On Treatment of Major Depressive Disorder (MDD)
- Schering-Plough Announces Asenapine NDA Accepted for Filing by the U.S. FDA
- Vanda Pharmaceuticals Receives FDA Acceptance of Iloperidone New Drug Application
- Forest Laboratories, Inc. Announces Positive Results of LEXAPRO(R) Phase III Study in Adolescents With Major Depression
- Alpharma’s Phase III Pivotal Clinical Placebo-Controlled Trial of Its Abuse-Deterrent, Extended-Release Opioid Demonstrates Significant Efficacy
- FDA Approves Cymbalta(R) for Maintenance Treatment of Major Depressive Disorder
- Titan reports FDA acceptance of Iloperidone NDA
- Lexicon Initiates Phase 2A Trial of LX6171 Drug Candidate for Cognitive Disorders
- AVANIR Enrolls First Patient in Confirmatory Phase III Trial of Zenvia(TM) in PBA
- Neurocrine Receives Approvable Letter for Indiplon Capsules with Additional Safety and Efficacy Data Required by FDA
- Vanda Presents Phase III Iloperidone Efficacy Data
- MGI PHARMA Announces Aquavan NDA Accepted for Review by U.S. FDA
- Clinical Data Initiates Long-Term Safety Study for Vilazodone
- ACADIA Pharmaceuticals Announces Completion of Enrollment of ACP-104 Phase IIb Clinical Trial Ahead of Schedule
- New Study Results Show Asenapine More Effective Than Placebo in the Treatment of Acute Schizophrenia
- ACADIA Pharmaceuticals Announces Completion of Enrollment of ACP-104 Phase IIb Clinical Trial Ahead of Schedule
- Memory Pharmaceuticals Initiates Phase 2a Trial of MEM 3454 in Cognitive Impairment Associated with Schizophrenia
- INTRA-CELLULAR THERAPIES INITIATES PHASE 2 CLINICAL TRIAL FOR SLEEP MAINTENANCE INSOMNIA
- AstraZeneca Submits sNDAs for Seroquel XR™ for the Treatment of Bipolar Mania and Bipolar Depression
- Addex Announces ADX10059 Phase IIa Acute Anxiety Data
- Phase I Safety and Tolerability Study with EVT 302 Successfully Completed
- amarin to commence phase ii trial with amr101 in age associated memory impairment
- XenoPort and GlaxoSmithKline Report Positive Top-Line Results of Second Phase 3 Restless Legs Syndrome Trial for XP13512/GSK1838262
- Pfizer Statement on CHANTIX (varenicline) Labeling Update in the United States
- OVATION Receives Fast Track Designation for Sabril® to Treat Cocaine and Methamphetamine Dependence
- NovaDel\'s New Drug Application for ZolpiMist(TM) Oral Spray to Treat Insomnia Accepted for Filing by the U.S. Food and Drug Administration
- Catalyst Pharmaceutical Partners Announces Positive Phase II Trial Results for Vigabatrin in the Treatment of Cocaine Addiction
- Pfizer Japan Receives Manufacturing and Marketing Authorization for Champix(R)
- SOMAXON PHARMACEUTICALS SUBMITS NEW DRUG APPLICATION FOR SILENOR™ FOR THE TREATMENT OF INSOMNIA
- Jazz Pharmaceuticals, Inc. Announces Submission of Complete Response to FDA Approvable Letter for LUVOX(R) CR
- FDA Alerts Health Care Providers to Risk of Suicidal Thoughts and Behavior with Antiepileptic Medications
- Study Suggests Risperidone Long-Acting Injection Combined with Standard Treatment Helped Delay Time to Relapse in Patients with Bipolar Disorder
- FDA Issues Public Health Advisory on Chantix
- BioLineRx Announces Positive Results from Phase 2a Trial of BL-1020, a GABA-Enhanced Antipsychotic for the Treatment of Schizophrenia
- Alexza Initiates AZ-007 (Staccato(R) Zaleplon) Phase 1 Clinical Trial and Updates Clinical Pipeline Development Status
- Neurogen Announces R&D Update
- Labopharm Reports Positive Results for Phase III Study on Once-daily Trazodone
- Alexza Initiates First Phase 3 Clinical Trial for AZ-004 (Staccato(R) Loxapine)
- XenoPort and GlaxoSmithKline Report Positive Top-Line Results of Final Pivotal Trial of XP13512/GSK1838262 for Restless Legs Syndrome
- FDA Issues Not-Approvable Letter for Lilly\'s Zyprexa® Long-Acting Injection (LAI) for Schizophrenia Treatment
- Evotec Starts Phase II in Smoking Cessation with EVT 302
- FDA Accepts for Review OVATION\'s Two NDA Submissions for Sabril
- AstraZeneca Submits sNDA for Seroquel XR™ for the Treatment of Major Depressive Disorder
- FDA approves LUVOX® CR (fluvoxamine maleate) extended-release capsules for the treatment of social anxiety disorder (SAD) and obsessive compulsive disorder (OCD)
- U.S. Food and Drug Administration Approves ABILIFY® (aripiprazole) for the Acute Treatment of Manic and Mixed Episodes Associated with Bipolar I Disorder in Pediatric Patients (10 to 17 Years of Age)
- FDA Approves Pristiq for the Treatment of Adult Patients with Major Depressive Disorder
- Medivation\'s Dimebon(TM) Stabilizes Behavioral Symptoms in Alzheimer\'s Disease Patients, Resulting in Reduced Caregiver Distress
- Targacept Initiates Clinical Development of TC-5214 as Augmentation Therapy for Major Depressive Disorder
- EPIX Pharmaceuticals Announces Discontinuation of PRX-00023 Clinical Development Program
- CORCEPT THERAPEUTICS ANNOUNCES COMMENCEMENT OF NEXT PHASE 3 STUDY WITH CORLUX® FOR THE TREATMENT OF PSYCHOTIC DEPRESSION
- Evotec\'s EVT 101 Shown to Penetrate the Brain in Man and to Modulate Brain Activity during the Performance of Cognitive Tasks
- Announces Start of Ph II Efficacy Trial for Rufinamide SYN-111
- Study Suggests INVEGA (paliperidone) Helps Patients With Schizophrenia Maintain Symptom Control
- ACADIA Pharmaceuticals Initiates Second Phase III Trial with Pimavanserin in Patients with Parkinson\'s Disease Psychosis
- Arena Pharmaceuticals Initiates Phase 2b Clinical Trial of APD125 for the Treatment of Insomnia
- Supplemental New Drug Application for RISPERDAL(R) CONSTA(R) Submitted to the FDA for the Treatment of Frequently Relapsing Bipolar Disorder
- SOMAXON PHARMACEUTICALS ANNOUNCES ACCEPTANCE FOR FILING OF NEW DRUG APPLICATION FOR SILENOR™ FOR THE TREATMENT OF INSOMNIA
- Antares Pharma\'s Partner to Initiate Phase III Trial for CNS Therapy in Q4 2008
- Opexa Therapeutics Presents Tovaxin Phase I/II Data at the American Academy of Neurology 60th Annual Meeting
- BrainCells Inc. Initiates Phase 2 Clinical Trial with BCI-540 for Depression with Anxiety
- Biovail Receives FDA Approval for Aplenzin (BVF-033)
- ARYx Therapeutics Enters Clinic with Novel Antipsychotic Drug for Patients with Schizophrenia
- Alexza Completes Enrollment in Phase 2a Clinical Trial With AZ-002 (Staccato(R) Alprazolam) in Panic Disorder Patients
- Targacept Announces Designation of Lead Compound in Smoking Cessation Program
- Roche Exercises its Option to Further Develop and Commercialize Memory Pharmaceuticals Nicotinic Alpha-7 Agonist, MEM 3454
- FDA ADVISORY COMMITTEE VOTES IN FAVOR OF APPROVAL OF FOSPROPOFOL DISODIUM INJECTION FOR SEDATION
- Arena Pharmaceuticals, Inc. Announces Initiation of Phase 1 Clinical Trial of Drug Candidate Under Partnership with Taisho Pharmaceutical Co., Ltd.
- Results of the Phase III Pivotal Study of VYVANSE™ for the Treatment of ADHD in Adults Presented at National Scientific Meeting of Psychiatrists
- New Analysis in Boys and Girls Shows the ADHD Patch, DAYTRANA Offered ADHD Symptom Control for 12 Months
- ABILIFY(R) (aripiprazole) Receives Expanded Indications for Maintenance Treatment in Both Pediatric Patients (Aged 10-17) With Manic and Mixed Episodes of Bipolar I Disorder and Adolescents (Aged 13-17) With Schizophrenia
- FDA Approves AstraZeneca’s Seroquel for Maintenance Treatment in Bipolar Disorder
